GT19077 / Kintor Pharma - LARVOL DELTA

Proffered Paper: Targeting MYC with the Novel Molecular Glue, GT19630 for the Treatment of Breast Cancer (EACR-AACR 2024) - "IC50 values for GT19630 were an order of magnitude lower than that for 3 previously described MYC-MAX antagonists, i.e., MYCi975 (p < 0.0001), MYCMI-6 (p < 0.0001), or GT19077 (p < 0.0001), i.e., GT19630 was a significantly more potent inhibitor than the 3 MYC-MAX antagonist investigated. Finally, we found that GT19630 degraded the negative immune checkpoint protein B7-H3 which has been implicated in immune evasion. Conclusion Based on our findings, we conclude that GT19630 should be an effective inhibitor of breast cancer cell growth."

Breast Cancer • Oncology • Solid Tumor • Targeted Protein Degradation • CD276 • GSPT1 • MYC

Kintor Pharma Announces Two Upcoming Poster Presentations at AACR 2022 (PRNewswire) - "Kintor Pharmaceutical Limited...announced two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022, including proxalutamide to treat COVID-19 and a c-Myc Degrader to treat blood cancer and small cell lung cancers (SCLC). This year's AACR annual meeting will be held in the city of New Orleans, United States, on April 8-13, 2022."

Preclinical • Hematological Malignancies • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

[VIRTUAL] Discovery of GT19077, a c-Myc/Max protein-protein Interaction (PPI) small molecule inhibitor, and GT19506 a c-Myc PROTAC molecule, for targeting c-Myc-driven blood cancers and small cell lung cancers (AACR 2021) - "In conclusion, GT19077 and GT19506 are currently in Lead Optimization Phase, which demonstrate the desired selectivity of targeting Myc dependent B-cell malignancies and Myc-amplified SCLC, but sparing c-Myc in growth factor/cytokine regulated blood progenitor cells. The defined selectivity has enabled the ongoing in vivo efficacy studies, currently GT19077 and GT19506 have being evaluated in in vivo efficacy studies."

IO biomarker • Hematological Malignancies • Lung Cancer • Lymphoma • Neuroendocrine Tumor • Non-Hodgkin’s Lymphoma • Oncology • Small Cell Lung Cancer • Solid Tumor • CD47 • MYC • MYCL • MYCN

[VIRTUAL] Discovery of GT19077, a c-Myc/Max Protein-Protein Interaction (PPI) Small Molecule Inhibitor, for Targeting c-Myc-Driven Blood Cancers (ASH 2020) - "GT19077 was also much less active at degrading c-Myc in GM-CSF-stimulated TF-1 or IL-2-stimulated lymphoid progenitor NK-92 cells assayed by WB. These results can help develop biomarkers for patient tailoring strategy. Finally, GT19077 demonstrates PK-dependent target engagement in vivo and is currently being evaluated in in vivo efficacy studies."

IO Biomarker • Burkitt Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • FGFR • IL2 • KRAS • MYC